FREQUENTLY ASKED QUESTIONS AND ANSWERS ABOUT CANCER REPORTING AND THE HIPAA PRIVACY RULE

1. What is the HIPAA Privacy Rule?

In 1996 the U.S. Congress passed a law requiring, among other things, uniform federal privacy protections for individually identifiable health information. This law is called the Health Insurance Portability and Accountability Act of 1996, or "HIPAA." The U.S. Department of Health and Human Services recently issued final regulations implementing the privacy provisions of HIPAA. These regulations are called the "Privacy Rule." Copies of the HIPAA Privacy Rule, as well as helpful explanatory materials, may be found at the HHS Office of Civil Rights website: http://www.hhs.gov/ocr/hipaa/.

2. What is a ‘Public Health Authority’ under HIPAA?

Under HIPAA, a ‘Public Health Authority’ refers to “an agency or authority of the United States, a State or territory, a political subdivision of a State or territory, or an Indian tribe, or a person or entity acting under a grant of authority from or contract with such public agency, including the employees or agents of such public agency or its contractors or persons or entities to whom it has granted authority, that is responsible for public health matters as part of its official mandate.”

Such agencies are authorized by law to collect or receive such information for the purposes of preventing or controlling disease, injury, vital events such as birth or death, and the conduct of public health surveillance, public health investigations, and public health interventions.

Central cancer registries are considered public health authorities because state laws mandate their duties.

3. What is a ‘Covered Entity’ under HIPAA?

A ‘Covered Entity’ is a health care plan, a healthcare clearinghouse, or a health care provider who transmits any health information in electronic form for financial and administrative transactions. A ‘health care provider’ is “a provider of medical or health services, and any other person who furnishes, bills or is paid for health care in the normal course of business.”

This information was prepared on behalf of NAACCR members by individuals active in national, state, regional and hospital cancer registry organizations in consultation with legal counsel and with information provided by US federal officials involved in interpretation and implementation of the HIPAA Privacy Rule. This document should not be considered official government policy and is subject to change. Rev. 3/31/03
4. Is it a violation of HIPAA for a covered entity to report information about cases of cancer to the state cancer registry?

No. Reporting information about cases of cancer in accordance with the requirements of state authorizing statutes and regulations is permitted by HIPAA. The Privacy Rule contains a specific provision authorizing covered entities to disclose protected health information as required by law.\(^1\) In fact, penalties for failure to comply with state reporting are specified in state law and often consist of significant fines.

\(^{145\text{ CFR 164.512(a)(1)}}\)

5. Since HIPAA is federal, will it override the state laws?

No. HIPAA does not obstruct any state law that supports or mandates the reporting of diseases or injury for public health purposes.

6. Is there specific legal documentation that supports the requirement to release cancer patient information to any agency?

Individual state laws and regulations document cancer reporting requirements. Central registries should consult their state laws and regulations regarding release of cancer patient information.

7. What, if any, are the consequences of not cooperating with state cancer registry requests for new cancer case information?

HIPAA does not obstruct any state law that supports or mandates the reporting of diseases or injury for public health purposes. Penalties for failing to comply with state reporting are specified in the state law and often consist of significant fines.

8. Does HIPAA require covered entities to obtain written authorization from the individual before reporting protected health information to the state cancer registry?

No. The provision of the Privacy Rule authorizing disclosure of protected health information as required by law is an exception to the requirement for written authorization.\(^1\)

\(^{145\text{ CFR 164.512(a)(1)}}\)
9. How does HIPAA impact the data collection of non-reportable/benign diseases (i.e. benign brain, CIN III, Co-morbid conditions)?

HIPAA does not obstruct any state law that supports or mandates the reporting of any disease.

10. Are private practice physicians still required to report new cancer cases?

Yes, in compliance with state reporting regulations. The central cancer registry has a reportable list that identifies which cancers are reportable, and all reportable cancers should be reported, as required by state law.

11. Will private practice physicians and hospitals be permitted to continue to provide follow-up and treatment information to hospital cancer registries without patient authorization?

Yes. Although private practice physicians and hospitals are health providers, and thus covered under the provisions of the HIPAA privacy regulations, they may continue to provide cancer patient follow-up and treatment information to hospital cancer registries without patient authorization when both the physician and the hospital has or had a relationship with the patient.

Under the HIPAA Final Privacy Rule, private practice physicians and hospitals may disclose confidential patient information to hospitals for the purpose of treatment, payment and health care operations (emphasis added) (quality assessment/improvement is considered a health care operation). A business associate agreement is not required between a hospital and physician for such purposes (emphasis added).

Section 164.506(c)(4), states, in relevant part, that

"A Covered Entity may disclose protected health information to another covered entity for health care operations activities of the entity that receives the information, if each entity either has or had a relationship with the individual who is the subject of the protected health information being requested, the protected health information pertains to such relationship, and the disclosure is:

(i) For a purpose listed in paragraph (1) or (2) of the definition of health care operations Section 164.501 of the Privacy Rule defines health care operations and Paragraph (1) of the definition provides, in relevant part:
(1) Conducting quality assessment and improvement activities, including outcomes evaluation and development of clinical guidelines, **population-based activities related to improving health** (emphasis added) or reducing health care costs, protocol development, case management and case coordination, contacting of health care providers and patients with information about treatment alternatives; and related functions that do not include treatment.

Paragraph (2) of the definition provides, in relevant part:

(2) Reviewing the competence or qualifications of health care professionals, evaluating practitioner and provider performance, health plan performance, conducting training programs in which students, trainees, or practitioners in areas of health care learn under supervision to practice or improve their skills as health care providers, training of non-health care professionals, accreditation, certification, licensing, or credentialing activities.

Thus, as hospital cancer registries collect treatment and follow-up data in compliance with state law and for the purpose of “population-based activities related to improving health” this is a permitted disclosure without requirement of patient authorization. It may also be noted that many hospital cancer registries collect this information for “conducting quality assessment and improvement activities”, for “reviewing the competence or qualifications of health care professionals”, for “conducting training programs” and for “accreditation, certification, licensing, or credentialing activities”. All of these are specifically permitted in paragraphs (1) and (2) shown above.

Note that Section 164.506(c)(4) specifically provides for the ability of one covered entity to provide an individual's PHI to another covered entity, if the receiving covered entity “has or had” a relationship with the individual. This specific reference to the past tense is important since it means that a covered entity's ability to obtain information about a patient need not be "cut-off" if the patient no longer has a direct relationship with the covered entity.

While exchange of treatment and follow-up information is permitted without patient authorization under the provisions described above, an accounting of disclosure must still be maintained.

\[1\] 45 CFR 160.103
12. What if a patient does not want follow-up information to be collected?

State-mandated cancer reporting typically does not require patient informed consent nor can individuals elect to be removed from reporting. In a state which allows the collection of follow-up cancer data for public health purposes, it can be collected regardless of consent from a patient.

13. Once HIPAA is in place, will pathology labs be able to continue to send new cancer case information to the state cancer registry?

Yes. Public health reporting under the authority of state law is specifically exempted from HIPAA rules.

14. If the government–authorized public health entity is not located in the same state as the covered entity, is it still ok under HIPAA to provide the data?

Yes, it is not prohibited. In fact, the definition of a ‘public health entity’ was broadened in the section “Uses and Disclosures for Public Health Activities”, which states specifically “…We broaden the scope of allowable disclosures …by allowing covered entities to disclose protected health information not only to U.S. public health authorities but also, at the direction of a public health authority, to an official of a foreign government agency that is acting in collaboration with a public health authority.”

1,2

1 45 CFR 164.512
2 FR p. 82525

15. Are covered entities required to determine whether the information about cases of cancer reported to the state cancer registry is the "minimum necessary" information required to be disclosed?

No. The Privacy Rule does include a general requirement that covered entities make reasonable efforts to limit the disclosure of protected health information to the minimum necessary to accomplish the intended purpose of the disclosure.¹ However, there is a specific exception to this requirement for disclosures that are required by law, such as the reporting of information about cases of cancer to the state cancer registry pursuant to state law and regulations.²

¹ 45 CFR 164.502(b)(1)
² 45 CFR 164.502(b)(2)(v)
16. What information is required for a covered entity to meet the Privacy Rule's verification requirements with respect to reporting information about cases of cancer to the state cancer registry?

The Privacy Rule requires covered entities to verify a requester's identity before disclosing protected health information. In the case of disclosure to a person acting on behalf of a public official, a covered entity that reasonably relies on a written statement on appropriate government letterhead that the requester is acting under the government's authority will fulfill this requirement. The Privacy Rule also requires covered entities to verify the requester's authority. A covered entity that reasonably relies on a written statement of the legal authority under which the information is requested will fulfill this requirement. To assist covered entities in meeting the verification requirements, the state cancer registry may elect to provide a written statement to cancer reporting facilities with the aforementioned information.

17. Are covered entities required to sign "business associate agreements" with regional or state cancer registries that perform on-site abstracting and cancer data reporting?

HIPAA requires business associate agreements with entities that carry out health care functions on behalf of covered entities, but state and regional registries are acting on behalf of the state when they provide on-site abstracting and reporting services, not the covered entity. Therefore, they are not business associates.

18. Does HIPAA apply to the use or disclosure of information about cancer cases after it has been reported to the state cancer registry?

No. The Privacy Rule applies to disclosure of protected health information by covered entities as required by law; state cancer registries are not covered entities. However, state cancer registry authorizing legislation typically includes strict limits on use and disclosure of reported information.

___________________________

This information was prepared on behalf of NAACCR members by individuals active in national, state, regional and hospital cancer registry organizations in consultation with legal counsel and with information provided by US federal officials involved in interpretation and implementation of the HIPAA Privacy Rule. This document should not be considered official government policy and is subject to change. Rev. 3/31/03
19. Are covered entities required to provide individuals upon request with an accounting of any protected health information that the entity has disclosed about them to the state cancer registry?

Yes. The Privacy Rule requires covered entities to provide an accounting of disclosures of protected health information.\(^1\) The accounting must include for each disclosure:

- The date of the disclosure
- The name of the entity or person who received the protected health information and, if known, the address of such entity or person
- A brief description of the protected health information disclosed
- A brief statement of the purpose of the disclosure that reasonably informs the individual of the basis for the disclosure or, in lieu of such statement, a copy of a written request for a disclosure under §164.502(a)(2)(ii) or 164.512, if any.\(^1\)

\(^{1}\)45 CFR 164.528
August 15, 2001

Holly L. Howe, PhD.
Executive Director
North American Association
of Central Cancer Registries
2121 W. White Oaks Dr., Suite C
Springfield, Illinois 62708

Re: The Federal Privacy Rule's Application to Central Cancer Registries

Dear Dr. Howe:

At your request, we have reviewed the letter dated July 13, 2001, which you received from Professor James Hodge of the Georgetown University Law Center. As discussed by Professor Hodge, federal regulations, entitled Standards for Privacy of Individually Identifiable Health Information (the "Privacy Rule"), restrict the use and disclosure of health information by health care providers, health plans, and health care clearinghouses.1 After reviewing the relevant regulations, Professor Hodge concluded that the Privacy Rule does not restrict the disclosure of patient information by a health care provider to a central cancer registry so long as the central cancer registry is a "public health authority." We agree with that conclusion.

On July 6, 2001, the U.S. Department of Health and Human Services ("DHHS") issued its Guidance on the Privacy Rule and on the issue addressed by Professor Hodge.2 DHHS concluded that disclosures to public health authorities are permitted under the Privacy Rule, and among various Questions and Answers, stated:

1 45 C.F.R. § 164.500 et. seq.

2 Guidance on Standards for Privacy of Individually Identifiable Health Information, issued by the U.S. Department of Health and Human Services, at pg. 54 (July 6, 2001).
Q: Must a health care provider or other covered entity obtain permission from a patient prior to notifying public health authorities of the occurrence of a reportable disease?

A: No. All states have laws that require providers to report cases of specific diseases to public health officials. The Privacy Rule allows disclosures that are required by law. Furthermore, disclosures to public health authorities that are authorized by law to collect or receive information for public health purposes are also permissible under the Privacy Rule. In order to do their job of protecting the health of the public, it is frequently necessary for public health officials to obtain information about the persons affected by a disease. In some cases they may need to contact those affected in order to determine the cause of the disease to allow for actions to prevent further illness.

The Privacy Rule continues to allow for the existing practice of sharing protected health information with public health authorities that are authorized by law to collect or receive such information to aid them in their mission of protecting the health of the public. Examples of such activities include those directed at the reporting of disease or injury, reporting deaths and births, investigating the occurrence and cause of injury and disease, and monitoring adverse outcomes related to food, drugs, biological products and dietary supplements. (emphasis added).

As explained by DHHS in its Guidance, the Privacy Rule allows disclosure of information to public health authorities. With respect to the disclosure of information to central cancer registries, and as noted by Professor Hodge, whether the Privacy Rule restricts the disclosure of information depends on whether each central cancer registry falls within the definition of a "public health authority." A public health authority is defined as:

an agency or authority of the United States, a State or territory, a political subdivision of a State or territory, or an Indian tribe, or a person or entity acting under a grant of authority from or contract with such public agency...that is responsible for public health matters as part of the official mandate.3 (emphasis added).

3 45 C.F.R. §164.501
Since state cancer registries come within this definition, the Privacy Rule does not restrict disclosure of patient information to them. For the exemption to apply to a non-governmental registry, however, the registry must operate pursuant to a contract with a public agency or under a grant of authority from a public agency.

Should you have any further questions regarding this issue, please advise.

Very truly yours,

[Signature]

Jeffery M. Wilday

JMW:ddh
July 13, 2001

Holly L. Howe, PhD
Executive Director
North American Association of Central Cancer Registries
2121 West White Oaks Dr, Suite C
Springfield, Illinois 62704

Re: Disclosure of Protected Health Information to Cancer Registries Under Federal Health Information Privacy Protections Pursuant to the Health Insurance Portability and Accountability Act of 1996 (HIPAA)

Dear Dr. Howe:

Thank you for this opportunity to address on behalf of the North American Association of Central Cancer Registries (NAACCR) a prevailing, legal issue that has arisen pursuant to the new federal health information privacy standards developed by the Department of Health and Human Services (DHHS) with Congressional authorization under the Health Insurance Portability and Accountability Act of 1996 (HIPAA).

This issue may be succinctly stated as follows: Do the new federal health information privacy regulations limit the disclosure of individually-identifiable health information (namely cancer data) by medical providers and others to cancer registries for public health uses? For the reasons set forth below, I conclude that the HIPAA privacy regulations do not substantially limit these disclosures unless the recipient cancer registry is not a public health authority (as defined below). In fact, the HIPAA privacy regulations encourage and support the disclosure of individually-identifiable cancer data without specific, informed consent for public health purposes.

After Congress failed to meet a self-imposed deadline under HIPAA to enact a relevant privacy statute, DHHS assumed authority under the Act to develop regulations to protect the privacy of individually-identifiable health information. The regulations were finally approved by

1
President Bush on April 12, 2001. The official, effective date of the regulations is April 14, 2001. Covered entities (discussed below) have two (2) years to fully comply (or by April 14, 2003), except for small health plans, who have until April 14, 2004 to comply.2

The HIPAA privacy regulations set forth privacy rules for the acquisition, use, storage, and disclosure of individually-identifiable health information (a.k.a. "protected health information") in paper or electronic form. Protected health information includes individually-identifiable information relating to cancer diagnoses, tests, and treatments. If health information is non-identifiable (i.e., it cannot be identified to any individual), it is not covered by the HIPAA privacy regulations principally because the use and exchange of such data raises little or no individual privacy concerns.

The regulations govern the acts of covered entities. Covered entities include health care providers (e.g. hospitals, physicians, laboratories) who transmit any health information in electronic form pursuant to certain financial and administrative transactions.4 Most hospitals and physicians typically rely on some form of electronic billing or information exchange, and thus fall under the requirements of the Act.

Concerning disclosures, the HIPAA privacy regulations set forth a standard rule: protected health information shall not be disclosed without the written, informed consent of the individual who is the subject of the information. However, DHHS recognizes several exceptions to this general rule to allow disclosures for various communal goods, including disclosures made for public health purposes.

The "public health" exemption states that a covered entity may disclose protected health information without specific, individual informed consent to a "public health authority that is authorized by law to collect and receive such information for the purpose of preventing and controlling disease, injury, or disability, including . . . reporting of disease . . . and the conduct of public health surveillance . . . ."5 Provided that a cancer registry fits the definition of a public health authority, the registries' acquisition of identifiable cancer data for surveillance or other

---

1 Statement by DHHS Secretary Tommy G. Thompson Regarding the Patient Privacy Rule. April 12, 2001.
3 45 C.F.R. § 160.103 (defining health care provider in reference to two other acts as well as to include "any person or organization who furnishes, bills, or is paid for health care in the normal course of business").
4 45 C.F.R. § 164.104.
legitimate public health purposes is protected under the exemption, and thus does not require individual informed consent.

A public health authority is defined as an:

agency or authority of the United States, a State, a territory, a political subdivision of a State or territory, or an Indian tribe, or a person or entity acting under a grant of authority from or contract with such public agency ... that is responsible for public health matters as part of its official mandate.  

This definition clearly applies to central or regional cancer or tumor registries operated by a state or local department of health, or as a freestanding, state-supported agency. A public health authority also includes some private sector entities that perform public health functions (like cancer surveillance) pursuant to a grant of authority or contract with a governmental public health agency.

Since most cancer or tumor registries would be considered public health authorities, covered entities under HIPAA may disclose protected health information to these registries without the individual informed consent of each patient pursuant to the "public health" exemption to HIPAA general disclosure rule.

However, any non-governmental entity that performs services similar to government-supported cancer registries, but is not acting under a grant of authority from or does not contract with a public agency, would likely not come under the exemption.  

This conclusion is affirmed by the pre-emption provisions in the HIPAA privacy regulations. The privacy regulations expressly do not pre-empt (or override) state law that "provides for the reporting of disease or injury ... or for the conduct of public health surveillance [or] investigation ... " Thus, state law that permits covered entities to disclose identifiable information to cancer registries without individual informed consent remains intact. This further supports a cancer registry’s ability to collect protected health information without the patient’s informed consent where state law allows the registry to do so.

---


7 See DHHS, Section 164.512(b) -- Uses and Disclosures for Public Health Activities, in Section-by-Section Discussion of Comments, Preamble Part III of Standards of Privacy of Individually Identifiable Information (June 28, 2001) <http://aspe.hhs.gov/admnsimp/final/PvcPre03.htm> (responding to the first comment listed).

While HIPAA does not limit disclosures of protected health information to cancer registries, the Act requires covered entities to log these and many other disclosures. This minimal requirement preserves the individual’s right to review an accounting of disclosures of their health information over a certain period of time (generally six years).

I hope that this opinion letter clarifies the effect of the new HIPAA privacy regulations concerning the disclosure of individually-identifiable health information to cancer registries from hospitals, physicians, laboratories, and other medical providers. In summary, the regulations allow for these disclosures without specific, informed consent provided the cancer registry is a public health authority. Please let me know your questions, comments, or concerns related to this opinion. You may reach me via email at jhodge@jh.edu, or via phone, (410) 955-7624.

With best wishes,

James G. Hodge, Jr., J.D., LL.M.
Adjunct Professor of Law, Georgetown University Law Center
Assistant Scientist, the Johns Hopkins School of Public Health

Researchers in medical and health-related disciplines require access to many sources of health information, from archived medical records and epidemiological databases to disease registries, tissue repositories, hospital discharge records, and government compilations of vital and health records. As the Privacy Rule is implemented, researchers are asking how these rules might affect research that uses records within databases and repositories.

As of April 14, 2003, the Privacy Rule requires many health care providers and health insurers to obtain additional documentation from researchers before disclosing health information to them, and to scrutinize researchers’ requests for access to health information more closely. Although the Privacy Rule introduces new rules for the use and disclosure of health information by covered entities for research, researchers can help to enable their continued access to health data by understanding the Privacy Rule and assisting health care entities covered by the Privacy Rule in meeting its requirements.

This fact sheet discusses the Privacy Rule and its potential to affect the creation of research databases and repositories, and research that uses identifiable health information in repositories and databases. Additional information about the Privacy Rule’s potential impact on other research activities, such as clinical research, health services research, institutional review boards (IRBs) and Privacy Boards can be found in related publications, including:

- Protecting Personal Health Information in Research: Understanding the HIPAA Privacy Rule
- Health Services Research and the HIPAA Privacy Rule
- Clinical Research and the HIPAA Privacy Rule
- Institutional Review Boards and the HIPAA Privacy Rule
- Privacy Boards and the HIPAA Privacy Rule

### Introduction to the Privacy Rule

In response to a congressional mandate in the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the Department of Health and Human Services (HHS) issued regulations entitled, Standards for Privacy of Individually Identifiable Health Information. For most covered entities, compliance with these regulations, known as the Privacy Rule, was required as of April 14, 2003.

The Privacy Rule is a response to public concern over potential abuses of the privacy of health information. The Privacy Rule establishes a category of health information, referred to as protected health information (PHI), which may be used or disclosed to others only in certain circumstances or under certain conditions. PHI is a subset of what is termed individually identifiable health information. With certain exceptions, the Privacy Rule applies to individually identifiable health information created or maintained by a covered entity. Covered entities are health plans, health care clearinghouses, and health care providers that transmit health information electronically in connection with certain defined HIPAA transactions, such as claims or eligibility inquiries. Researchers are not themselves covered entities, unless they are also health care providers and engage in any of the covered electronic transactions. If, however, researchers are employees or other workforce members of a covered entity (e.g., a covered hospital or health insurer), they may have to comply with that entity’s HIPAA privacy policies and procedures. Researchers who are not themselves covered entities, or who are not workforce members of covered entities, may be indirectly affected by the Privacy Rule if covered entities supply their data. In addition, it should be noted that the HHS and the Food and Drug Administration’s (FDA) Protection of Human Subjects Regulations (45 CFR part 46 and 21 CFR parts 50 and 56, respectively) may also apply to research involving the development or use of research repositories and associated data.

### Overview of the Privacy Rule’s Impact on Repositories and Databases

The Privacy Rule was not intended to impede research using records within databases and repositories that include individuals’ health information, but the Privacy Rule does place new conditions on the use and disclosure of PHI by covered entities for research. It is important to recognize that the creation of a research database or repository, and the use or disclosure of PHI from a database or repository for research, may each be considered a research activity under the Privacy Rule. For more specific information about how the Privacy Rule could affect health services research, refer to the related publication, Health Services Research and the HIPAA Privacy Rule.
It is important to recognize that the Privacy Rule permits covered entities, such as hospitals, clinics, and other health care providers to continue amassing information on their patients for treatment, payment, and health care operations purposes, and to put this information into their own databases without Authorization. The Privacy Rule also allows the disclosure of PHI to government-authorized public health authorities for disease surveillance, disease prevention, and other public health purposes, such as reporting disease and injury. When required by law, other disclosures are permitted, for example, state-mandated reporting to cancer registries. Covered entities may also continue to disclose PHI for adverse event and related reports to FDA and others for public health purposes (see section 164.512 of the Privacy Rule and additional information at http://www.cdc.gov/mmwr/early_release.html). Thus, many databases that are now used for records research will continue to be maintained and updated and will remain available to records researchers, although in some cases, under new terms.

The Privacy Rule permits a covered entity to use or disclose PHI for research under the following circumstances and conditions:

- For reviews preparatory to research if certain representations are obtained from the researcher.
- For research solely on decedents’ information if certain representations are obtained from the researcher.
- If the subject of the PHI has granted specific written permission through an Authorization.
- If the covered entity receives appropriate documentation that an IRB or Privacy Board has granted a waiver or an alteration of the Authorization requirement.
- If the PHI has been de-identified in accordance with the standards set by the Privacy Rule (in which case, the health information is no longer PHI).
- If the information is released in the form of a limited data set, with certain identifiers removed, and with a data use agreement between the researcher and the covered entity.
- If informed consent of the individual to participate in the research, an IRB waiver of such informed consent, or other express legal permission to use or disclose the information for the research is grandfathered by the transition provisions.

For some records and database research, Authorization may not be needed. Some of the most important exceptions to the Authorization requirement that pertain to research using repositories and databases are the waiver of Authorization and the limited data set.

**Waiver or Alteration of the Authorization Requirement by an IRB or Privacy Board**

For some types of research, it may be impracticable for researchers to obtain written Authorization from research participants, for example, for some research conducted on existing databases or repositories where no contact information is available. To address these situations, the Privacy Rule contains criteria for the waiver or alteration of the Authorization requirement by an IRB or another review body called a Privacy Board. The Privacy Rule permits a covered entity to use or disclose PHI for research purposes without Authorization (or with an altered Authorization), if the covered entity received proper documentation that an IRB or Privacy Board has granted a waiver (or an alteration) of the Authorization requirement for the research use or disclosure of PHI. The Privacy Rule establishes criteria to be evaluated by an IRB or Privacy Board in approving an Authorization waiver or alteration. For a covered entity to use or disclose PHI under a waiver or alteration of the Authorization requirement, it must receive documentation of, among other things, the IRB or Privacy Board’s determination that the following criteria have been met:

- The PHI use or disclosure involves no more than a minimal risk to the privacy of individuals based on at least the presence of: (1) An adequate plan presented to the IRB or Privacy Board to protect PHI identifiers from improper use and disclosure; (2) An adequate plan to destroy those identifiers at the earliest opportunity, consistent with the research, absent a health or research justification for retaining the identifiers or if retention is otherwise required by law; and (3) Adequate written assurances that the PHI will not be reused or disclosed to any other person or entity except (a) as required by law, (b) for authorized oversight of the research study, or (c) for other research for which the use or disclosure of the PHI is permitted by the Privacy Rule;
- The research could not practicably be conducted without the requested waiver or alteration; and,
- The research could not practicably be conducted without access to and use of the PHI.

**De-identified Data Sets**

The Privacy Rule permits covered entities to release data that have been de-identified without obtaining an Authorization and without further restrictions upon use or disclosure because de-identified data is not PHI and,
The second way is to have a qualified statistician determine, using generally accepted statistical and scientific principles and methods, that the risk is very small that the information could be used, alone or in combination with other reasonably available information, by the anticipated recipient to identify the subject of the information. The qualified statistician must document the methods and results of the analysis that justify such a determination.

It is important to note that the Privacy Rule permits a covered entity to assign to, and retain with, the de-identified health information, a code or other means of record re-identification if that code is not derived from or related to the information about the individual and is not otherwise capable of being translated to identify the individual. For example, an encrypted individual identifier (e.g., a social security number) would not meet the conditions for use as a re-identification code for de-identified health information because it is derived from individually identified information. (See 67 Federal Register 53233, August 14, 2002.) In addition, the covered entity may not: (1) Use or disclose the code or other means of record identification for any purposes other than as a re-identification code for the de-identified data, and (2) disclose its method of re-identifying the information.

Limited Data Sets

Where only certain identifiers are needed, it may be permissible for a covered entity to provide a researcher with a limited data set. Limited data sets are data sets stripped of certain direct identifiers that are specified in the Privacy Rule. Limited data sets may be used or disclosed only for public health, research, or health care operations purposes. They are not de-identified information under the Privacy Rule. Importantly, unlike de-identified data, protected health information in limited data sets may include the following: Addresses other than street name or street address or post office boxes; all elements of dates (such as admission and discharge dates) and unique codes or identifiers not listed as direct identifiers. Before disclosing a limited data set to a researcher, a covered entity must enter into a data use agreement with the researcher, identifying the researcher as the recipient of the limited data set, establishing how the data may be used and disclosed by the recipient, and providing assurances that the data will be protected, among other requirements. If the covered entity learns that the researcher has violated this agreement, the entity must take reasonable steps to end or repair the violation and, if such steps are unsuccessful, stop disclosing PHI to the researcher and report the problem to the HHS Office for Civil Rights. Additional information on limited data sets and data use agreements can be found in the booklet, Protecting Personal Health Information in Research: Understanding the HIPAA Privacy Rule.

Activities Preparatory to Research

Additionally, covered entities may permit researchers to review PHI in medical records or elsewhere to prepare a research protocol, or for similar purposes preparatory to research. This review allows the researcher to determine, for example, whether a sufficient number or type of records exists to conduct the research. Importantly, the covered entity may not permit the researcher to remove any PHI from the covered entity. To permit the researcher to conduct a review preparatory to research, the covered entity must receive from the researcher representations that:

- The use or disclosure is sought solely to review PHI as necessary to prepare the research protocol or other similar preparatory purposes;
- No PHI will be removed from the covered entity during the review; and,
- The PHI that the researcher seeks to use or access is necessary for the research purposes.

Additional information on activities preparatory to research can be found in the publications, Protecting Personal Health Information in Research: Understanding the HIPAA Privacy Rule and Clinical Research and the HIPAA Privacy Rule.

Research Involving Decedents’ PHI

A covered entity may provide access to decedents’ records for research purposes if the covered entity receives from the researcher: Representations that the decedents’ PHI is necessary for the research and is being sought solely for research on the PHI of decedents (not, for example, living relatives of decedents); and, upon request of the covered entity, documentation of the deaths of the study subjects. No Authorization or alteration or waiver of Authorization by an IRB or Privacy Board is needed for use or disclosure of PHI for research only on the PHI of deceased persons, if these conditions are met.
Other Privacy Rule Requirements

Minimum Necessary Standard
When using or disclosing PHI for research without an Authorization, a covered entity must make reasonable efforts to limit the PHI used or disclosed to the minimum necessary amount to accomplish the research purpose. If an IRB or Privacy Board has granted the researcher a waiver or an alteration of Authorization, a covered entity may reasonably rely upon the researcher’s request consistent with the description of PHI in documentation from the IRB or Privacy Board as the minimum necessary amount of PHI for the research. Additional information on the minimum necessary standard can be found in the booklet, Protecting Personal Health Information in Research: Understanding the HIPAA Privacy Rule.

Right to an Accounting of Disclosures
The Privacy Rule grants individuals new rights, including the right to receive an accounting of disclosures made for research by a covered entity without the individual’s Authorization (e.g., under a waiver of Authorization), except for disclosures of a limited data set. The individual has a right to such an accounting of disclosures made by a covered entity in the 6 years prior to the date on which the accounting is requested, not including the period prior to the compliance date. For such disclosures, in general, individuals who request an accounting must be told what PHI was disclosed, to whom it was disclosed, and the date and purpose of the disclosure. Covered entities must provide the address of the recipient, if known.

For certain research disclosures made by a covered entity, two other options exist for providing an accounting. When multiple disclosures of PHI are made to the same person or entity for a single purpose, the accounting for such disclosures may consist of the information described above for the first disclosure, plus the number or frequency of disclosures, and the date of the last disclosure during the time period covered by the request.

If, during the period covered by the accounting, the covered entity has disclosed the records of 50 or more individuals for a particular research purpose, the covered entity may provide a more general accounting to the requestor. The covered entity would provide the following information in the general accounting:

• The name and description of the protocols for which their PHI may have been disclosed,
• A brief description of the type of PHI disclosed,
• The date or period of time of the disclosures,
• The contact information of the researcher and the research sponsor, and
• A statement that the PHI of the individual may or may not have been disclosed for a particular protocol or research activity.

Section 164.528(b)(4)(ii) of the Privacy Rule requires that, upon request, the covered entity must help the individual contact the sponsor and researcher when it is reasonably likely that the individual’s PHI was disclosed for a particular protocol. Additional information on accounting of disclosures can be found in the booklet, Protecting Personal Health Information in Research: Understanding the HIPAA Privacy Rule.

Frequently Asked Questions and Answers

Q: Are tissue repositories “covered entities?”
A: Not unless the organization maintaining the tissue repository conducts some other activity that makes it a covered entity. For example, tissue repositories that conduct testing of specimens for the benefit of transplant recipients based on another health care provider’s orders would be covered providers under HIPAA if they conduct electronic transactions for which the HHS has adopted standards.

Q: A researcher does not receive names, addresses, social security or medical record numbers, or other obvious identifiers from data sources. If the IRB has not considered this data to be individually identifiable in the past, and thus, determined that the research was not human subjects research under 45 CFR part 46, or that the research was exempt under 45 CFR 46.101(b), will this change under the Privacy Rule?
A: No. The Privacy Rule does not change the applicability or the requirements of the HHS and FDA Protection of Human Subjects Regulations. However, where the information sought by the researcher is held by a covered entity, the covered entity’s use or disclosure of that information is subject to the Privacy Rule, unless the information is de-identified by the Privacy Rule’s standards. The Privacy Rule’s de-identification safe-harbor method is likely more stringent than what has been applied in the past to render information no longer identifiable for research purposes. De-identification under the Privacy Rule’s safe-harbor standard may be accomplished through the removal of all 18 identifiers (section 164.514(b)(2) of the Privacy Rule).
Alternatively, fewer identifiers may need to be removed for health information to be de-identified if a qualified statistician determines that the risk of re-identification is very small (section 164.514(b)(1) of the Privacy Rule). The Privacy Rule also permits a covered entity to retain, with the de-identified health information, a code for re-identification as long as the code is not related to or derived from information about the individual and is not otherwise capable of being translated to identify the individual, and as long as the covered entity does not disclose its method of re-identification or use or disclose its code for other purposes (section 164.514(c) of the Privacy Rule). For example, a randomly assigned re-identification code would not make the de-identified information to which it is assigned PHI, because a random code would not be derived from or related to information about the individual.

Where a researcher needs data elements that would render the information identifiable under the Privacy Rule, but where certain direct identifiers (set forth in section 164.514(e)) are not needed, a limited data set may be sufficient for the research. A limited data set is information stripped of only the direct identifiers listed at section 164.514(e), which include, but are not limited to, the name and street address of the individual. To use or disclose a limited data set, the covered entity must enter into a data use agreement with the recipient of the information.

In practice, this means that records research that may not require IRB approval under the HHS Protection of Human Subjects Regulations, still may require an Authorization or a waiver of Authorization under the Privacy Rule, or be subject to a data use agreement if a limited data set is used or disclosed.

Q: How may a covered entity use or disclose PHI for the creation of a research repository or database when it is unknown at the time of collection what specific protocols will make use of the repository or database in the future?

A: There are two separate activities to consider: (1) The use or disclosure of PHI for creating a research database or repository and (2) The subsequent use or disclosure of PHI in the database for a particular research protocol.

A covered entity’s use or disclosure of PHI to create a research database or repository, and use or disclosure of PHI from the database or repository for a future research purpose, are each considered a separate research activity under the Privacy Rule. In general, the Privacy Rule requires Authorization for each activity, unless, for example, an IRB or Privacy Board waives or alters the Authorization requirement. (See Overview of Privacy Rule’s Impact on Repositories and Databases.) Documentation of a waiver or an alteration of Authorization to use or disclose PHI to create a research database requires, among other things, a statement that an IRB or Privacy Board has determined that the researcher has provided adequate written assurances that PHI in the database will not be further used or disclosed except as permitted by the Privacy Rule (e.g., for research uses and disclosures with an Authorization or waiver). A covered entity also could use or disclose a limited data set to create a research repository or database under conditions set forth in a data use agreement.

For subsequent use or disclosure of PHI for research purposes from a repository or database maintained by the covered entity, the covered entity may:

- Obtain the individual’s Authorization for the research use or disclosure of PHI as specified under section 164.508.
- Obtain documentation of an IRB or Privacy Board’s waiver of the Authorization requirement that satisfies section 164.512(i).
- Obtain satisfactory documentation of an IRB or Privacy Board’s alteration of the Authorization requirement as well as the altered Authorization from the individual.
- Use or disclose PHI for reviews preparatory to research with representations that satisfy section 164.512(i)(1)(ii) of the Privacy Rule.
- Use or disclose PHI for research on decedents’ PHI with representations that satisfy section 164.512(i)(1)(iii) of the Privacy Rule.
- Provide a limited data set and enter into a data use agreement with the recipient as specified under section 164.514(e).
- Use or disclose PHI based on permission obtained prior to the compliance date of the Privacy Rule—informed consent of the individual to participate in the research; an IRB waiver of such informed consent; or Authorization or other express legal permission to use or disclose the information for the research as specified under section 164.532(c) of the Privacy Rule.

A covered entity may also use or disclose PHI from databases and repositories for other purposes without Authorization as permitted by the Privacy Rule, such as if required by law or to a public
A single Authorization can cover uses and disclosures of PHI for multiple activities of a specific research study, including the collection and storage of tissues for that study. In addition, where two different research studies are involved, such as where a research study collects information for the study itself and also collects and stores PHI in a central repository for future research, the Privacy Rule generally would permit them to be combined into a single, compound Authorization form. However, a compound Authorization is not allowed where the provision of research-related treatment, payment, or eligibility for benefits is conditioned on only one of the Authorizations, and not the other. See section 164.508(b)(3)(iii) of the Privacy Rule. For example, a covered entity that conducts an interventional clinical trial that also involves collecting tissues and associated PHI for storage in a central repository for future research would not be permitted to obtain a compound Authorization for both research purposes if research-related treatment is conditioned upon signing the Authorization for the clinical trial. Any compound Authorization must clearly specify the different research studies covered by the Authorization so the individual is adequately informed.

If the transition provisions do not apply and the information is not de-identified, subsequent uses and disclosures of PHI from databases and repositories held by covered entities generally require an individual’s Authorization unless otherwise permitted by the Privacy Rule (e.g., with a waiver of Authorization or as a limited data set).

In addition, if the database or repository, which is held or maintained by a covered entity, contains only de-identified health information (which may include a re-identification code) meeting the Privacy Rule’s requirements at section 164.514(a)-(c), the Privacy Rule does not apply.

A covered entity has a research repository and database of individually identifiable data for which the IRB waived informed consent for its creation and subsequent uses and disclosures of identifiable data prior to April 14, 2003. Is the covered entity required to obtain Authorization for research use and disclosure of PHI from the repository or database after April 14, 2003?
A: No, because the waiver, as described, meets the transition provisions of the Privacy Rule at 164.532(c). However, if informed consent is being sought from specimen donors after the compliance date, Authorization by the donors will be needed unless an IRB approves a waiver of the Authorization requirement, or another permitted use or disclosure applies.

Q: Does the Privacy Rule apply to databases held by covered entities that only receive de-identified participant data?

A: No, so long as the health information is de-identified according to the Privacy Rule, the Privacy Rule does not apply to the database or to future uses and disclosures of de-identified data from the database.

Q: May ongoing longitudinal studies continue after April 14, 2003?

A: Yes. Permissions or waivers obtained prior to the Privacy Rule’s compliance date of April 14, 2003, for ongoing longitudinal studies are grandfathered by the Privacy Rule if they meet the transition provisions at 164.532(c). For many such uses and disclosures of PHI in connection with ongoing research, a covered entity may rely on any one of the following that was obtained prior to the compliance date:

- An Authorization or other express legal permission from an individual to use or disclose PHI for research;
- The informed consent of the individual to participate in the research; or
- A waiver by an IRB of informed consent in accordance with applicable laws and regulations governing informed consent, unless informed consent is sought after the compliance date.

Q: A researcher requests data that assigns a code derived from the last four digits of the social security number. This code is necessary to link individual records from different data sources. The data contain none of the other listed HIPAA identifiers at section 164.514(b)(2). Are the data de-identified under the Privacy Rule?

A: No. Under the Privacy Rule, a de-identified data set may not contain unique identifying codes, except for codes that have not been derived from or do not relate to information about the individual and that cannot be translated so as to identify the individual. A code derived from part of a social security number, medical record number, or other identifier would not meet this test.

Q: Does the Privacy Rule permit a covered entity to de-identify health information or create a limited data set without obtaining Authorization, waiver of the Authorization requirement from an IRB or Privacy Board, or representations for reviews preparatory to research?

A: Yes. In the Privacy Rule, creating de-identified health information or a limited data set is a health care operation of the covered entity, and thus, does not require the covered entity to obtain an individual’s Authorization, a waiver of the Authorization requirement, or representations for reviews preparatory to research. If a business associate is hired by a covered entity to de-identify health information or create a limited data set, such activity must be conducted in accordance with the business associate requirements at sections 164.502(e) and 164.504(e).

Q: What is a limited data set, and what are its advantages?

A: A limited data set is PHI that does not include a specified list of direct identifiers. The limited data set is not considered to be de-identified information, and unlike de-identified information, a limited data set may include identifiers such as ZIP codes, elements of dates, and unique identifiers not listed as direct identifiers at section 164.514(e). The advantage of a limited data set is that even though it is not de-identified, it can still be used or disclosed for research purposes without an Authorization or a waiver of the Authorization requirement. A covered entity must, however, enter into a data use agreement with the recipient of the limited data set before using or disclosing it. (See section 164.514(e) of the Privacy Rule.)

Q: What types of information (direct identifiers) must be omitted from PHI in order to qualify the information as a limited data set?

A: All the following direct identifiers of the individual or of relatives, employers, or household members of the individual must be removed:

- Name.
- Street name or street address or post office box (i.e., not including city, state, or ZIP code).
- Telephone and fax numbers.
- Email address.
- Social security number.
- Certificate/license numbers.
Vehicle identifiers and serial numbers.
URLs and IP addresses.
Full-face photos and other comparable images.
Medical record numbers, health plan beneficiary numbers, and other account numbers.
Device identifiers and serial numbers.
Biometric identifiers, including finger and voice prints.

Q: What is the difference between a de-identified data set and a limited data set?

A: A de-identified data set is one in which either: (1) The 18 identifiers specified in 164.514(b)(2)(i) have been removed and the covered entity does not have actual knowledge that the information could be used alone or in combination with other information to identify the individual (safe harbor method); or (2) A person with appropriate knowledge of and experience with generally accepted statistical and scientific principles and methods for rendering information not individually identifiable, determines the risk is very small that the information could be used by the recipient, alone or in combination with other reasonably available information, to identify an individual (section 164.514(b)(1)), and documents the basis for such determination. A de-identified data set is not protected by the Privacy Rule and may be used and disclosed without restriction.

A limited data set is one that excludes the direct identifiers in 164.514(e)(2). Unlike a de-identified data set, a limited data set is PHI because it may include dates, city, state, and ZIP codes, and other unique identifying codes or characteristics not listed as direct identifiers. A limited data set may be used or disclosed, without Authorization, for research, public health, or health care operations purposes, in accordance with section 164.512(e), only if the covered entity and limited data set recipient enter into a data use agreement. However, if the use or disclosure could be made under another provision of the Privacy Rule, such as for public health purposes in accordance with section 164.512(b), such agreement would not be required.

Q: Can a limited data set include the geographic subdivision code with the five-digit ZIP code (or a nine-digit ZIP code)?

A: Yes, the limited data set may include the five-digit or nine-digit ZIP code plus any other geographic subdivision, such as state, county, city, precinct, and their equivalent geocodes, except for street name or street address or post office box.

Q: Can a covered entity use or disclose PHI to locate or identify the whereabouts of a research participant (e.g., subjects who are “lost to follow-up”)?

A: A covered entity is permitted to use or disclose PHI to identify or locate the whereabouts of a research participant during the study as long as the use or disclosure is not limited in the individual’s Authorization (or grandfathered prior permission, if relevant) or waiver or alteration of Authorization. In addition, such use or disclosure is permissible if, for example, it is necessary for treatment of the individual or for a permissible public health purpose.

Q: What special requirements apply to research involving PHI from mental health providers?

A: The Privacy Rule provides individuals special protection for psychotherapy notes, which are notes recorded by a mental health provider that document or analyze counseling session conversations and that are maintained separately from the medical record. Unless the covered provider obtained, prior to the compliance date, the individual’s informed consent or other express legal permission for the research or an IRB waiver of informed consent for the research, a covered entity may not use or disclose these notes for research without the individual’s written Authorization. Information in the medical record and certain types of information, even if maintained separately from the medical record (e.g., information about test results, length and frequency of treatment, diagnosis, symptoms, or progress), is excluded from the definition of psychotherapy notes and may be released to researchers who obtain an Authorization or a waiver of Authorization from an IRB or Privacy Board, as part of a limited data set, or if appropriate, for reviews preparatory to research or for research involving decedent’s information where required representations are obtained. Special requirements also apply to compound
authorization involving the use or disclosure of psychotherapy notes. (See section 164.508(b)(3)(ii) of the Privacy Rule.) Various state laws governing the use or disclosure of mental health records, including psychotherapy notes, which are more stringent than the Privacy Rule provisions, may also apply.

Q: How does the Privacy Rule apply to research involving blood or tissue samples?

A: Under the Privacy Rule, neither blood nor tissue, in and of itself, is considered individually identifiable health information; therefore, research involving only the collection of blood or tissue would not be subject to the Privacy Rule’s requirements. Remember, however, blood and tissue are often labeled with information (e.g., admission date or medical record number) that the Privacy Rule considers individually identifiable and thus, PHI. A covered entity’s use or disclosure of this information for research is subject to the Privacy Rule. In addition, the results from an analysis of blood and tissue, if containing or associated with individually identifiable information, would be PHI.

Q: Do the transition provisions apply to a surgical consent obtained by a covered provider that was signed or agreed to prior to the removal of tissues that were later added to a repository?

A: Yes, the transition provisions would apply in this case if, in the surgical consent or other express legal permission, the individual specifically agreed to the use and disclosure of his or her PHI for research.

Q: Do the transition provisions at section 164.532(c) of the Privacy Rule apply to informed consent or waiver of informed consent to store and use PHI in a repository or database that was obtained before the compliance date?

A: Yes. HHS has stated, “...some express legal permissions and informed consents have not been study-specific and sometimes authorize the use or disclosure of information for future unspecified research. Furthermore, some IRB-approved waivers of informed consent have been for future unspecified research. Therefore, the final Rule at [section] 164.532 permits covered entities to rely on an express legal permission, informed consent, or IRB-approved waiver of informed consent for future unspecified research, provided the legal permission, informed consent or IRB-approved waiver was obtained prior to the compliance date.” (See 67 Federal Register 53226, August 14, 2002.)

Q: Does the Privacy Rule limit, to specific types of research studies, disclosures permitted as preparatory to research or for research on decedents’ information?

A: No. The Privacy Rule does not limit the types of research studies that may rely upon the provisions for reviews preparatory to research or for research on decedents’ information set forth at section 164.512(i). However, representations made to satisfy these provisions must include, among other requirements at sections 164.512(i)(1)(ii) and 164.512(i)(1)(iii), a statement that the use or disclosure of protected health information is “necessary for the research purposes.”

Q: Does the Privacy Rule restrict access for research purposes to information held by the Medicaid or SCHIP programs?

A: Yes. Local and state Medicaid authorities are covered entities under HIPAA, as are the State Children’s Health Insurance Program (SCHIP) programs. These agencies or programs are covered under the Privacy Rule because they are listed in the Privacy Rule’s definition of a “health plan.” All SCHIP programs and state Medicaid agencies must consequently comply with the Privacy Rule; if they are hybrid entities, they must ensure that their designated health care components comply with the Privacy Rule. These government units will have some mechanism (a privacy officer, a Privacy Board, and/or an IRB) for controlling access to PHI for research purposes. A researcher will need to identify the responsible party and discuss with that office or official the ways in which access to PHI may be granted for research.

Q: In conducting records research, will a researcher who is a covered entity still be required to comply with state laws relating to medical records privacy, such as state HIV/AIDS confidentiality laws?

A: Probably. If the state law does not conflict with the Privacy Rule, the state law is not pre-empted by HIPAA, and the covered entity will be required to comply with both the state law and the Privacy Rule. If the state law conflicts with a provision of the Privacy Rule, the Privacy Rule has a preemption provision that allows state medical privacy laws to remain in place, if they are more stringent than the federal privacy standards. The Privacy Rule does not prohibit states from adopting privacy protec-
tions that are more stringent than the federal privacy standards.

Q: I am a researcher, and my research data source is asking me to sign a business associate agreement. Is this necessary?

A: Business associates are persons who perform certain services for, or functions or activities on behalf of, the covered entity that require access to PHI, but who are not part of the workforce of the covered entity. If the data source is not a covered entity, no business associate contract is required because the Privacy Rule only applies to covered entities.

If the data source is a covered entity, whether a business associate contract is required depends on the services, functions, or activities that the researcher is providing to or performing for the covered entity. Researchers are not business associates solely by virtue of their own research activities (although they may become business associates in some other capacity, e.g., if de-identifying PHI on behalf of a covered entity). A business associate agreement will typically be a legally enforceable contract, so a researcher may wish to consult legal counsel before signing one.

Q: Does a covered entity need to account for disclosures of PHI contained in a limited data set?

A: No. The accounting requirement does not apply to limited data set disclosures.

---

1 The following identifiers of the individual or of relatives, employers, or household members of the individual must be removed: (1) Names; (2) all geographic subdivisions smaller than a state, except for the initial three digits of the ZIP code if the geographic unit formed by combining all ZIP codes with the same three initial digits contains more than 20,000 people; (3) all elements of dates except year, and all ages over 89 or elements indicative of such age; (4) telephone numbers; (5) fax numbers; (6) email addresses; (7) social security numbers; (8) medical record numbers; (9) health plan beneficiary numbers; (10) account numbers; (11) certificate or license numbers; (12) vehicle identifiers and license plate numbers; (13) device identifiers and serial numbers; (14) URLs; (15) IP addresses; (16) biometric identifiers; (17) full-face photographs and any comparable images; (18) any other unique, identifying characteristic or code, except as permitted for re-identification in the Privacy Rule.

2 A person with appropriate knowledge of and experience with generally accepted statistical and scientific principles and methods for rendering information not individually identifiable.

3 The following direct identifiers must be removed for PHI to qualify as a limited data set: (1) Names; (2) postal address information, other than town or city, state, and ZIP code; (3) telephone numbers; (4) fax numbers; (5) email addresses; (6) social security numbers; (7) medical record numbers; (8) health plan beneficiary numbers; (9) account numbers; (10) certificate or license numbers; (11) vehicle identifiers and license plate numbers; (12) device identifiers and serial numbers; (13) URLs; (14) IP addresses; (15) biometric identifiers; and (16) full-face photographs and any comparable images.
Public Law 102-515  
102d Congress

An Act  

Entitled the "Cancer Registries Amendment Act".

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the "Cancer Registries Amendment Act".

SEC. 2. FINDINGS AND PURPOSE.

(a) FINDINGS.—Congress finds that—

(1) cancer control efforts, including prevention and early detection, are best addressed locally by State health departments that can identify unique needs;

(2) cancer control programs and existing statewide population-based cancer registries have identified cancer incidence and cancer mortality rates that indicate the burden of cancer for Americans is substantial and varies widely by geographic location and by ethnicity;

(3) statewide cancer incidence and cancer mortality data, can be used to identify cancer trends, patterns, and variation for directing cancer control intervention;

(4) the American Association of Central Cancer Registries (AACCR) cites that of the 50 States, approximately 38 have established cancer registries, many are not statewide and 10 have no cancer registry; and

(5) AACCR also cites that of the 50 States, 39 collect data on less than 100 percent of their population, and less than half have adequate resources for insuring minimum standards for quality and for completeness of case information.

(b) PURPOSE.—It is the purpose of this Act to establish a national program of cancer registries.

SEC. 3. NATIONAL PROGRAM OF CANCER REGISTRIES.

Title III of the Public Health Service Act (42 U.S.C. 241 et seq.) is amended by adding at the end the following new part:

"PART M—NATIONAL PROGRAM OF CANCER REGISTRIES

SEC. 399H. NATIONAL PROGRAM OF CANCER REGISTRIES.

(a) IN GENERAL.—The Secretary, acting through the Director of the Centers for Disease Control, may make grants to States, or may make grants or enter into contracts with academic or nonprofit organizations designated by the State to operate the State’s cancer registry in lieu of making a grant directly to the State, to support the operation of population-based, statewide cancer registries in order to collect, for each form of in-situ and invasive cancer (with the exception of basal cell and squamous cell carcinoma of the skin), data concerning—
“(1) demographic information about each case of cancer;
“(2) information on the industrial or occupational history of the individuals with the cancers, to the extent such information is available from the same record;
“(3) administrative information, including date of diagnosis and source of information;
“(4) pathological data characterizing the cancer, including the cancer site, stage of disease (pursuant to Staging Guide), incidence, and type of treatment; and
“(5) other elements determined appropriate by the Secretary.
“(b) Matching Funds.—
“(1) In general.—The Secretary may make a grant under subsection (a) only if the State, or the academic or nonprofit private organization designated by the State to operate the cancer registry of the State, involved agrees, with respect to the costs of the program, to make available (directly or through donations from public or private entities) non-Federal contributions toward such costs in an amount that is not less than 25 percent of such costs or $1 for every $3 of Federal funds provided in the grant.
“(2) Determination of amount of non-Federal contribution; maintenance of effort.—
“(A) Non-Federal contributions required in paragraph (1) may be in cash or in kind, fairly evaluated, including plant, equipment, or services. Amounts provided by the Federal Government, or services assisted or subsidized to any significant extent by the Federal Government, may not be included in determining the amount of such non-Federal contributions.
“(B) With respect to a State in which the purpose described in subsection (a) is to be carried out, the Secretary, in making a determination of the amount of non-Federal contributions provided under paragraph (1), may include only such contributions as are in excess of the amount of such contributions made by the State toward the collection of data on cancer for the fiscal year preceding the first year for which a grant under subsection (a) is made with respect to the State. The Secretary may decrease the amount of non-Federal contributions that otherwise would have been required by this subsection in those cases in which the State can demonstrate that decreasing such amount is appropriate because of financial hardship.
“(c) Eligibility for Grants.—
“(1) In general.—No grant shall be made by the Secretary under subsection (a) unless an application has been submitted to, and approved by, the Secretary. Such application shall be in such form, submitted in such a manner, and be accompanied by such information, as the Secretary may specify. No such application may be approved unless it contains assurances that the applicant will use the funds provided only for the purposes specified in the approved application and in accordance with the requirements of this section, that the application will establish such fiscal control and fund accounting procedures as may be necessary to assure proper disbursement and accounting of Federal funds paid to the applicant under subsection (a) of this
section, and that the applicant will comply with the peer review requirements under sections 491 and 492.

“(2) ASSURANCES.—Each applicant, prior to receiving Federal funds under subsection (a), shall provide assurances satisfactory to the Secretary that the applicant will—

“(A) provide for the establishment of a registry in accordance with subsection (a);

“(B) comply with appropriate standards of completeness, timeliness, and quality of population-based cancer registry data;

“(C) provide for the annual publication of reports of cancer data under subsection (a); and

“(D) provide for the authorization under State law of the statewide cancer registry, including promulgation of regulations providing—

“(i) a means to assure complete reporting of cancer cases (as described in subsection (a)) to the statewide cancer registry by hospitals or other facilities providing screening, diagnostic or therapeutic services to patients with respect to cancer;

“(ii) a means to assure the complete reporting of cancer cases (as defined in subsection (a)) to the statewide cancer registry by physicians, surgeons, and all other health care practitioners diagnosing or providing treatment for cancer patients, except for cases directly referred to or previously admitted to a hospital or other facility providing screening, diagnostic or therapeutic services to patients in that State and reported by those facilities;

“(iii) a means for the statewide cancer registry to access all records of physicians and surgeons, hospitals, outpatient clinics, nursing homes, and all other facilities, individuals, or agencies providing such services to patients which would identify cases of cancer or would establish characteristics of the cancer, treatment of the cancer, or medical status of any identified patient;

“(iv) for the reporting of cancer case data to the statewide cancer registry in such a format, with such data elements, and in accordance with such standards of quality timeliness and completeness, as may be established by the Secretary;

“(v) for the protection of the confidentiality of all cancer case data reported to the statewide cancer registry, including a prohibition on disclosure to any person of information reported to the statewide cancer registry that identifies, or could lead to the identification of, an individual cancer patient, except for disclosure to other State cancer registries and local and State health officers;

“(vi) for a means by which confidential case data may in accordance with State law be disclosed to cancer researchers for the purposes of cancer prevention, control and research;

“(vii) for the authorization or the conduct, by the statewide cancer registry or other persons and organizations, of studies utilizing statewide cancer registry data,
including studies of the sources and causes of cancer, evaluations of the cost, quality, efficacy, and appropriateness of diagnostic, therapeutic, rehabilitative, and preventative services and programs relating to cancer, and any other clinical, epidemiological, or other cancer research; and

“(viii) for protection for individuals complying with the law, including provisions specifying that no person shall be held liable in any civil action with respect to a cancer case report provided to the statewide cancer registry, or with respect to access to cancer case information provided to the statewide cancer registry.

“(d) Relationship to Certain Programs.—

“(1) In General.—This section may not be construed to act as a replacement for or diminishment of the program carried out by the Director of the National Cancer Institute and designated by such Director as the Surveillance, Epidemiology, and End Results Program (SEER).

“(2) Supplanting of Activities.—In areas where both such programs exist, the Secretary shall ensure that SEER support is not supplanted and that any additional activities are consistent with the guidelines provided for in subsection (c)(2)(C) and (D) and are appropriately coordinated with the existing SEER program.

“(3) Transfer of Responsibility.—The Secretary may not transfer administration responsibility for such SEER program from such Director.

“(4) Coordination.—To encourage the greatest possible efficiency and effectiveness of Federally supported efforts with respect to the activities described in this subsection, the Secretary shall take steps to assure the appropriate coordination of programs supported under this part with existing Federally supported cancer registry programs.

“(e) Requirement Regarding Certain Study on Breast Cancer.—In the case of a grant under subsection (a) to any State specified in section 399K(b), the Secretary may establish such conditions regarding the receipt of the grant as the Secretary determines are necessary to facilitate the collection of data for the study carried out under section 399C.

“SEC. 399I. PLANNING GRANTS REGARDING REGISTRIES.

“(a) In General.—

“(1) States.—The Secretary, acting through the Director of the Centers for Disease Control, may make grants to States for the purpose of developing plans that meet the assurances required by the Secretary under section 399B(c)(2).

“(2) Other Entities.—For the purpose described in paragraph (1), the Secretary may make grants to public entities other than States and to nonprofit private entities. Such a grant may be made to an entity only if the State in which the purpose is to be carried out has certified that the State approves the entity as qualified to carry out the purpose.

“(b) Application.—The Secretary may make a grant under subsection (a) only if an application for the grant is submitted to the Secretary, the application contains the certification required in subsection (a)(2) (if the application is for a grant under such subsec-
tion), and the application is in such form, is made in such manner, and contains such agreements, assurances, and information as the Secretary determines to be necessary to carry out this section.

SEC. 399J. TECHNICAL ASSISTANCE IN OPERATIONS OF STATEWIDE CANCER REGISTRIES.

The Secretary, acting through the Director of the Centers for Disease Control, may, directly or through grants and contracts, or both, provide technical assistance to the States in the establishment and operation of statewide registries, including assistance in the development of model legislation for statewide cancer registries and assistance in establishing a computerized reporting and data processing system.

SEC. 399K. STUDY IN CERTAIN STATES TO DETERMINE THE FACTORS CONTRIBUTING TO THE ELEVATED BREAST CANCER MORTALITY RATES.

(a) IN GENERAL.—Subject to subsections (c) and (d), the Secretary, acting through the Director of the National Cancer Institute, shall conduct a study for the purpose of determining the factors contributing to the fact that breast cancer mortality rates in the States specified in subsection (b) are elevated compared to rates in other States.

(b) RELEVANT STATES.—The States referred to in subsection (a) are Connecticut, Delaware, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island, Vermont, and the District of Columbia.

(c) COOPERATION OF STATE.—The Secretary may conduct the study required in subsection (a) in a State only if the State agrees to cooperate with the Secretary in the conduct of the study, including providing information from any registry operated by the State pursuant to section 399H(a).

(d) PLANNING, COMMENCEMENT, AND DURATION.—The Secretary shall, during each of the fiscal years 1993 and 1994, develop a plan for conducting the study required in subsection (a). The study shall be initiated by the Secretary not later than fiscal year 1994, and the collection of data under the study may continue through fiscal year 1998.

(e) REPORT.—Not later than September 30, 1999, the Secretary shall complete the study required in subsection (a) and submit to the Committee on Energy and Commerce of the House of Representatives, and to the Committee on Labor and Human Resources of the Senate, a report describing the findings and recommendations made as a result of the study.

SEC. 399L. AUTHORIZATION OF APPROPRIATIONS.

(a) REGISTRIES.—For the purpose of carrying out this part, the Secretary may use $30,000,000 for each of the fiscal years 1993 through 1997. Out of any amounts used for any such fiscal year, the Secretary may obligate not more than 25 percent for carrying out section 399J, and not more than 10 percent may be expended for assessing the accuracy, completeness and quality of data collected, and not more than 10 percent of which is to be expended under subsection 399J.
“(b) BREAST CANCER STUDY.—Of the amounts appropriated for the National Cancer Institute under subpart 1 of part C of title IV for any fiscal year in which the study required in section 399K is being carried out, the Secretary shall expend not less than $1,000,000 for the study.”.


LEGISLATIVE HISTORY–S. 3312:
  Oct. 2, considered and passed Senate.
  Oct. 5, considered and passed House, amended.
  Oct. 7, Senate concurred in House amendment.